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ABSTRACT
Introduction As white matter hyperintensities (WMHs) 
of the brain are associated with an increased risk of 
stroke, cognitive decline, and depression, elucidating the 
associated risk factors is important. In addition to age 
and hypertension, pre- diabetes and diabetes may play 
important roles in the development of WMHs. Previous 
studies have, however, shown conflicting results. We aimed 
to investigate the effect of diabetes status and quantitative 
markers of glucose metabolism on WMH volume in a 
population- based cohort without prior cardiovascular 
disease.
Research design and methods 400 participants 
underwent 3 T MRI. WMHs were manually segmented 
on 3D fluid- attenuated inversion recovery images. An 
oral glucose tolerance test (OGTT) was administered to 
all participants not previously diagnosed with diabetes 
to assess 2- hour serum glucose concentrations. Fasting 
glucose concentrations and glycated hemoglobin 
(HbA1c) levels were measured. Zero- inflated negative 
binomial regression analyses of WMH volume and 
measures of glycemic status were performed while 
controlling for cardiovascular risk factors and multiple 
testing.
Results The final study population comprised 388 
participants (57% male; age 56.3±9.2 years; n=98 
with pre- diabetes, n=51 with diabetes). Higher WMH 
volume was associated with pre- diabetes (p=0.001) 
and diabetes (p=0.026) compared with normoglycemic 
control participants after adjustment for cardiovascular 
risk factors. 2- hour serum glucose (p<0.001), but not 
fasting glucose (p=0.389) or HbA1c (p=0.050), showed 
a significant positive association with WMH volume after 
adjustment for cardiovascular risk factors.
Conclusion Our results indicate that high 2- hour 
serum glucose concentration in OGTT, but not fasting 
glucose levels, may be an independent risk factor for 
the development of WMHs, with the potential to inform 
intensified prevention strategies in individuals at risk of 
WMH- associated morbidity.
INTRODUCTION
In the past, white matter hyperintensities 
(WMHs) of the brain were considered 
incidental findings with unclear clinical 
significance. However, over the last decade, 
several studies have shown that WMHs are 
associated with multiple severe morbidities 
such as cognitive decline,1–3 increased 
stroke risk1 4 5 and worse outcome after 
stroke,6 decreased mobility due to gait 
disturbance7 as well as an increased risk of 
depression.8
Hypoperfusion due to altered cerebro-
vascular autoregulation, hypoxic–ischemic 
axonal loss and demyelination, as well as 
blood–brain barrier dysfunction have been 
established as leading pathophysiological 
causes of WMHs.9 10 A plethora of potential 
risk factors for WMHs have been described, 
including high age,11 12 hypertension,13–15 
dyslipoproteinemia,16 as well as socioeco-
nomic and lifestyle parameters.17–19 Also, 
diabetes and pre- diabetes might play a 
major role in the development of WMHs as 
diabetes- related atherosclerosis appears to 
be an essential driving factor.20–22 However, 
previous studies assessing the association 
between WMHs and diabetes status show 
conflicting results, with a large- scale study 
Significance of this study
What is already known about this subject?
 ► Diabetes contributes to the development of white 
matter hyperintensities (WMHs) of the brain.
What are the new findings?
 ► The effect of diabetes and particularly pre- diabetes 
on WMH volume may be driven by 2- hour serum 
glucose concentration determined by oral glucose 
tolerance test but not by fasting glucose levels.
How might these results change the focus of 
research or clinical practice?
 ► These results have the potential to inform intensified 
prevention strategies in individuals at risk of WMH- 
associated morbidity, explain conflicting results 
of studies assessing the effect of pre- diabetes on 
WMHs and show that future studies investigating 
the association between diabetes status and WMHs 
should differentiate between impaired glucose toler-
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demonstrating an association of WMH burden with 
diabetes, but not pre- diabetes,23 while another recent 
study did find an association with pre- diabetes.24 
These discrepancies might partially arise from the 
heterogeneous definition of diabetes status, which can 
be diagnosed based on 2- hour serum glucose concen-
trations in oral glucose tolerance tests (OGTTs) and/
or fasting glucose concentrations, or glycated hemo-
globin (HbA1c) levels.25 26
We therefore aimed to analyse the association of 
diabetes, pre- diabetes and WMHs more precisely, by 
detangling the effects of 2- hour glucose levels, fasting 
glucose concentrations, and HbA1c levels on WMH 
volume. In detail, the aims of this study were (1) to inves-
tigate the effect of diabetes status on WMH volume and 
(2) to assess the associations of 2- hour serum glucose 
concentration measured by OGTT, fasting glucose, as 
well as HbA1c with WMH volume, in order to inform 
intensified prevention strategies and to monitor early 




This study comprises a sample from the population- based 
Cooperative Health Research in the Region of Augsburg 
(KORA) FF4 study (2013–2014, 2279 participants). The 
FF4 study is the second follow- up of the baseline study 
KORA S4 (1999–2001, 4261 participants, response 67%), 
which represents a large sample from the general popu-
lation in the region of Augsburg, Germany. Recruit-
ment and data collection have been described in detail 
previously.27
Sample selection
The KORA MRI study nested in KORA FF4 included 400 
participants facilitating an enriched case–control design 
of 54 participants with established diabetes, 103 partic-
ipants with pre- diabetes and 243 with normal glucose 
metabolism. All 400 participants underwent a dedi-
cated whole- body MRI protocol, as described in detail 
previously.28
The KORA MRI study was designed with a focus on 
MRI- based analysis of subclinical disease burden before 
clinical symptoms become apparent. Consequently, 
participants with overt cardiovascular disease were not 
included in this study.28 Exclusion criteria of the KORA 
MRI study were age >74 years, validated/self- reported 
stroke, myocardial infarction, peripheral artery disease, 
type 1 diabetes, missing OGTT in participants without 
type 2 diabetes diagnosed by a physician before entering 
the KORA study, poor overall health condition, unwill-
ingness to undergo MRI, and contraindication to MRI 
(implanted stents, cardiac pacemaker or implantable 
defibrillator, cerebral aneurysm clip, neural stimulator, 
any type of ear implant, metal parts inside the body, larger 
tattoos, inability of supine position or breath- holding, 
known allergy to gadolinium compounds, serum creat-
inine level≥1.3 mg/dL, claustrophobia, pregnancy or 
breast feeding).28
In the present study, 12 participants had to be excluded 
due to insufficient MRI image quality (see online supple-
mental figure 1).
MRI
Image acquisition was performed on a single 3 T MRI 
system (Magnetom Skyra; Siemens Healthineers, 
Erlangen, Germany). T2- weighted 3D fluid- attenuated 
inversion recovery (FLAIR) images (slice thickness: 0.9 
mm, 0.5 mm×0.5 mm in- plane spatial resolution, repe-
tition time: 5000 ms, echo time: 389 ms, inversion time: 
1800 ms, flip angle: 120°) of the brain were acquired for 
WMH assessment, in accordance with the standards for 
reporting vascular changes on neuroimaging (STRIVE) 
recommendations.29
WMH volume
ITK- SNAP V.3.6.0 was used for segmentation.30 Cerebral 
WMHs were manually segmented by a radiology resi-
dent (SG, 2 years of experience in neuroimaging and 
radiology) and edited and modified where necessary by a 
board- certified radiologist (SSt, 7 years of experience in 
neuroimaging and radiology) on sagittal acquired FLAIR 
images reconstructed in axial plane with a slice thickness 
of 0.5 mm (see figure 1). For homogeneous image inten-
sity, the ITK- SNAP tool ‘autoadjust contrast’ was used. 
WMHs were defined as signal abnormalities of variable 
sizes in the white matter of the brain that show a hyperin-
tense signal on FLAIR images.29 WMH in the brainstem 
and cerebellum were not included. Image analyses were 
performed blinded to all clinical data as well as other 
measurements.
Pre-diabetes and diabetes assessment
Measures of pre- diabetes and diabetes were collected 
in a standardized method as part of the KORA study 
design and have been described in detail previously.27 
For the definition of pre- diabetes and diabetes, the 
Figure 1 Example of manual WMH segmentation (total 
WMH volume: 1835 mm3). (A) Axial T2- weighted fluid 
attenuated inversion recovery image of a participant in his 
50s. (B) Manual segmentation of WMH volume displayed in 
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WHO/International Diabetes Federation criteria were 
applied.25 Diabetes was determined as either established 
type 2 diabetes validated by a physician or a 2- hour serum 
glucose concentration determined by OGTT≥200 mg/
dL and/or a fasting glucose level >125 mg/dL. Pre- 
diabetes was determined as impaired glucose tolerance 
(IGT) and/or impaired fasting glucose (IFG) concentra-
tion. IGT was defined by a 2- hour serum glucose concen-
tration ranging between 140 and 199 mg/dL in OGTT. 
IFG was defined by fasting glucose levels ranging between 
110 and 125 mg/dL.
Fasting glucose concentration and the HbA1c value 
of each study participant were assessed. In addition, an 
OGTT was administered to all participants without previ-
ously diagnosed type 2 diabetes (n=354). Participants with 
type 2 diabetes diagnosed by a physician before entering 
the KORA study did not receive an OGTT (n=34). In 
17 participants, type 2 diabetes was newly diagnosed by 
OGTT within the KORA study.
Statistical analysis
Characteristics of the study population were summarized 
by arithmetic means with SD for continuous variables or 
counts and percentages for categorical variables, strati-
fied by diabetes status. Differences according to diabetes 
status were assessed by one- way analysis of variance or χ2 
test, where appropriate.
The associations between WMH volume (dependent 
variable) and diabetes status as well as 2- hour serum 
glucose concentration in OGTT, fasting glucose and 
HbA1c (independent variables) were evaluated sepa-
rately by zero- inflated negative binomial regression 
analysis. Models were unadjusted (model A), adjusted 
for age and gender (model B) and adjusted for age, 
gender, hypertension, low- density lipoprotein choles-
terol (LDL- C), Body Mass Index (BMI), smoking and 
alcohol consumption (model C), providing incidence 
rate ratios (IRRs) with 95% CIs. The IRR estimated 
the ratio of the predicted WMH volume for a one- 
unit increase in the risk factor variable. In sensitivity 
analyses, the associations between WMH volume and 
glycemic parameters were examined only in indi-
viduals with WMH by negative binomial regression 
models according to models A, B and C, separately. P 
values of <0.05 were considered to denote statistical 
significance. To account for multiple testing of the 
five independent variables (pre- diabetes, diabetes, 
2- hour glucose in OGTT, fasting glucose, and HbA1c), 
we additionally evaluated the results based on a signif-
icance level of p<0.01 (0.05/5). All analyses were 
conducted with Stata V.16.1.
RESULTS
Study population
The final study population consisted of 388 partici-
pants (57% male, age: 56.3±9.2 years), including 98 
(25%) participants with pre- diabetes and 51 (13%) 
participants with diabetes. WMHs were found in 70% 
of participants with pre- diabetes, 80% of participants 
with diabetes and 58% of control participants without 
pre- diabetes or diabetes. In total 249 (64.2%) partic-
ipants had detectable WMH. Mean WMH volume was 
2603 mm3 in participants with pre- diabetes, 3684 mm3 
in participants with diabetes and 996 mm3 in control 
participants without pre- diabetes or diabetes. Mean 
WMH volume across all participants was 1755 mm3. 
Further covariates such as age, gender, hypertension, 
LDL- C, BMI, smoking and alcohol consumption are 
presented in table 1.
An additional analysis applying of the definition of 
pre- diabetes and diabetes of the American Diabetes 
Association26 instead of the definition of the WHO/
International Diabetes Federation25 (ie, IFG was 
defined by fasting glucose levels ranging between 
100 and 125 mg/dL instead of 110 and 125 mg/dL) 
has been performed. Applying this lower cut- off, 160 
(41%) instead of 98 (25%) participants were diag-
nosed with pre- diabetes. WMHs were found in 68% 
instead of 70% of the participants with pre- diabetes. 
Mean WMH volume was 1893 mm3 instead of 2603 
mm3 in participants with pre- diabetes.
Differences in WMH volume between participants with 
diabetes, participants with pre-diabetes and normoglycemic 
control participants
WMH volume was significantly higher in participants 
with pre- diabetes and diabetes as compared with 
normoglycemic control participants (p<0.001, respec-
tively). These effects were confirmed after adjustment 
for age and gender (p=0.002 and p=0.005, respec-
tively), and after adjustment for age, gender, hyperten-
sion, LDL- C, BMI, smoking and alcohol consumption 
(p=0.001 and p=0.026, respectively) (see figure 2). 
There was no significant difference in WMH volume 
between pre- diabetic participants and participants 
with diabetes (p=0.406). Further details are presented 
in table 2.
These results were verified in a subgroup analysis 
based merely on participants with WMHs: compared with 
normoglycemic controls, WMH volume was significantly 
higher in individuals with pre- diabetes and diabetes 
(p<0.001, respectively). The association of WMH volume 
with pre- diabetes remained significant after adjustment 
for age, gender and cardiovascular risk factors (p=0.004). 
The association of WMH volume with diabetes was atten-
uated after adjustment for age, gender and cardiovas-
cular risk factors (p=0.077). Further details are presented 
in online supplemental table 1.
In an additional analysis under application of the 
definition for pre- diabetes and diabetes of the Amer-
ican Diabetes Association26 instead of the definition 
of the WHO/International Diabetes Federation25 
(ie, IFG was defined by fasting glucose levels ranging 
between 100 and 125 mg/dL instead of 110 and 125 
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in participants with pre- diabetes and diabetes as 
compared with normoglycemic control participants 
(p=0.047 and p<0.001, respectively). However, these 
effects became insignificant after adjustment for age 
and gender (p=0.351 and p=0.075, respectively), 
and after adjustment for age, gender, hypertension, 
LDL- C, BMI, smoking and alcohol consumption 
(p=0.379 and p=0.242, respectively). WMH volume 
was significantly higher in participants with diabetes 
as compared with participants with pre- diabetes 
(p=0.041). However, these effects became insignifi-
cant after adjustment for age and gender (p=0.215), 
and after adjustment for age, gender, hypertension, 
LDL- C, BMI, smoking and alcohol consumption 
(p=0.529). Further details are presented in online 
supplemental table 2.












WMH 249 (64.2%) 139 (58.2%) 69 (70.4%) 41 (80.4%) 0.004
WMH volume (mm3) 1755.4 (±5920.4) 996.4 (±2689.4) 2602.6 (±5931.6) 3684.2 (±12675) 0.003
Age (years) 56.3 (±9.2) 54.2 (±8.8) 58.4 (±8.8) 62 (±8.1) <0.001
Male gender 222 (57.2%) 123 (51.5%) 62 (63.3%) 37 (72.6%) 0.008
BMI (kg/m2) 28 (±4.7) 26.6 (±4.1) 30.4 (±4.7) 30.1 (±5) <0.001
Hypertension† 129 (33.3%) 49 (20.5%) 44 (44.9%) 36 (70.6%) <0.001
Systolic BP (mm Hg) 120.4 (±16.7) 116.7 (±15) 124 (±15) 131.3 (±21) <0.001
Diastolic BP (mm Hg) 75.3 (±10) 73.7 (±9.2) 77.6 (±9.6) 78.2 (±12.7) <0.001
Total cholesterol (mg/dL) 218.1 (±35.8) 216.5 (±35.3) 222.9 (±31) 216.8 (±45.5) 0.317
HDL (mg/dL) 62.3 (±17.6) 65.5 (±17.9) 58.6 (±14) 54.6 (±18.5) <0.001
LDL- C (mg/dL) 139.7 (±32.3) 138.6 (±31.5) 143.8 (±29.4) 136.8 (±40.2) 0.319
Triglycerides (mg/dL) 129.7 (±82) 107.1 (±63.8) 151.5 (±81.7) 193.4 (±110.6) <0.001
HbA1c (%) 5.6 (±0.7) 5.3 (±0.3) 5.6 (±0.3) 6.6 (±1.4) <0.001
Fasting serum glucose (mg/dL) 103.9±22.5 94.6±7.3 106.8±10.2 143.7±38.9 <0.001
Glucose after 2- hour OGTT (mg/
dL)
112.9 (±40.9) 94.3 (±20.3) 140.4 (±29.9) 216.7 (±64.3) <0.001
Smoking status 0.211
  Never smoker 143 (36.9%) 94 (39.3%) 32 (32.7%) 17 (33.3%)
  Former smoker 167 (43%) 92 (38.5%) 48 (49%) 27 (52.9%)
  Current smoker 78 (20.1%) 53 (22.2%) 18 (18.4%) 7 (13.7%)
Pack years 12.8 (±18.8) 11.1 (±16) 13.9 (±17.9) 19 (±29) 0.021
Physical activity in categories 0.003
  1=regularly more than 2 hours/
week
112 (28.9%) 79 (33.1%) 26 (26.5%) 7 (13.7%)
  2=regularly ca. 1 hour/week 120 (30.9%) 78 (32.6%) 32 (32.7%) 10 (19.6%)
  3=irregularly ca. 1 hour/week 57 (14.7%) 29 (12.1%) 14 (14.3%) 14 (27.5%)
  4=little or no physical activity 99 (25.5%) 53 (22.2%) 26 (26.5%) 20 (39.2%)
Alcohol 0.586
  No consumption 93 (24%) 58 (24.3%) 21 (21.4%) 14 (27.5%)
  <20 g/day 152 (39.2%) 100 (41.8%) 35 (35.7%) 17 (33.3%)
  20–40 g/day 75 (19.3%) 45 (18.8%) 19 (19.4%) 11 (21.6%)
  >40 g/day 68 (17.5%) 36 (15.1%) 23 (23.5%) 9 (17.7%)
Data are means and SD for continuous variables and counts and percentages for categorical variables.
*P values are from one- way analysis of variance and χ2 test, respectively.
†Hypertension was defined as systolic BP of ≥140 mm Hg, diastolic BP of ≥90 mm Hg and/or use of antihypertensive 
medication, given that the individuals were aware of being hypertensive.
BMI, Body Mass Index; BP, blood pressure; HbA1c, glycated hemoglobin; HDL, high- density lipoprotein; LDL- C, low- density 
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Associations of 2-hour serum glucose concentration 
determined by OGTT, fasting glucose concentration, and 
HbA1c with WMH volume
Two- hour serum glucose concentration determined by 
OGTT showed a significant association with WMH volume 
(p<0.001), which remained significant after adjustment 
for age, gender, hypertension, LDL- C, BMI, smoking 
and alcohol consumption (p<0.001). An increase of 1 
mg/dL in serum glucose was associated with a WMH 
volume increase of 1%. Fasting glucose was not signifi-
cantly associated with WMH volume before (p=0.710) 
and after adjustment for age, gender and cardiovascular 
risk factors (p=0.389). HbA1c showed a significant asso-
ciation with WMH volume (p<0.001), which was attenu-
ated after adjustment for age, gender and cardiovascular 
risk factors (p=0.050). Further details are presented in 
table 3.
In a subgroup analysis restricted to participants with 
WMHs (n=249), these results could be replicated: 2- hour 
serum glucose concentration determined by OGTT 
showed a significant association with WMH volume, 
which remained significant after adjustment for age, 
gender and cardiovascular risk factors (p<0.001). Fasting 
glucose concentration was not significantly associated 
with WMH volume (p=0.590). HbA1c was significantly 
associated with WMH volume before (p<0.001) but not 
after adjustment (p=0.074) (see figure 3). Further details 
are shown in online supplemental table 3.
In a subgroup analysis comprising only participants 
who received an OGTT (n=354), fasting glucose concen-
tration was again not significantly associated with WMH 
volume (p=0.886). HbA1c showed a significant associa-
tion with WMH volume (p<0.001), which remained signif-
icant after adjustment for age, gender and cardiovascular 
risk factors (p=0.005). Further details are presented in 
online supplemental table 4.
A subgroup analysis of participants with isolated IGT 
(n=44), isolated IFG (n=37) and combined IGT/IFG 
(n=17) confirmed these results: IGT, but not IFG, showed 
a significant association with WMH volume, which 
Figure 2 Predicted WMH volume (x- axis: diabetes status, y- axis: WMH volume) in normoglycemic controls (mean: 996 mm3), 
persons with pre- diabetes (mean: 2603 mm3) and diabetes (mean: 3684 mm3). WMH volume was significantly higher in persons 
with pre- diabetes (p=0.001) and diabetes (p=0.026) compared with normoglycemic controls after adjustment for age, gender, 
hypertension, low- density lipoprotein cholesterol, Body Mass Index, smoking, and alcohol consumption. WMH, white matter 
hyperintensity.
Table 2 Association of diabetes status with WMH volume
Participants with pre- diabetes versus 
normoglycemic control participants
Participants with diabetes versus 
normoglycemic control participants
Participants with pre- diabetes 
versus participants with diabetes
IRR (95% CI) P value IRR (95% CI) P value IRR (95% CI) P value
WMH 
volume
A 2.17 (1.48 to 3.17) <0.001 2.69 (1.70 to 4.25) <0.001 0.81 (0.48 to 1.34) 0.406
B 1.84 (1.26 to 2.70) 0.002 1.96 (1.22 to 3.16) 0.005 0.94 (0.58 to 1.51) 0.793
C 1.87 (1.28 to 2.75) 0.001 1.75 (1.07 to 2.87) 0.026 1.07 (0.66 to 1.72) 0.788
IRRs are from zero- inflated negative binomial regression models.
A, unadjusted; B, adjusted for age; C, adjusted for age, gender, hypertension, low- density lipoprotein cholesterol, Body Mass Index, 
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remained significant after adjustment for age, gender 
and cardiovascular risk factors (p<0.001). Combined 
IGT/IFG was significantly associated with WMH volume 
before (p=0.007) but not after adjustment for age and 
gender (p=0.188). However, the number of participants 
with combined IGT/IFG was low. Further details are 
shown in online supplemental tables 5 and 6.
DISCUSSION
In this enriched, population- based study, we investi-
gated the effect of diabetes status, as well as quantita-
tive markers of glucose metabolism, on WMH volume. 
Confounder adjusted analysis showed a significant associ-
ation between WMH volume and diabetes status. In addi-
tion, WMH volume was strongly associated with 2- hour 
glucose after OGTT but not with fasting glucose. HbA1c 
showed a significant association with WMH volume, 
which was attenuated after adjustment for age, gender 
and cardiovascular risk factors, depending on the under-
lying study sample.
WMH volume was significantly higher in individuals 
with pre- diabetes or diabetes compared with normo-
glycemic controls. The association between WMHs and 
diabetes status was confirmed after adjustment for age 
and gender. In the current literature, the effect of pre- 
diabetes on WMH volume is under debate: a recent large- 
scale study that defined diabetes status based on fasting 
glucose concentration and HbA1c levels demonstrated 
that severe diabetes, but not less- severe diabetes or pre- 
diabetes, was associated with increased WMH burden.23 
On the other hand, another large- scale study that defined 
diabetes status based on fasting glucose concentration 
and 2- hour glucose concentration in OGTT reported that 
pre- diabetes was associated with higher WMH burden, 
with further deterioration in type 2 diabetes.24
We found that high 2- hour serum glucose concentra-
tion determined by OGTT, but not fasting glucose, was 
strongly associated with increased WMH volume. This 
association remained highly significant after adjustment 
for traditional cardiovascular risk factors. This finding 
Table 3 Association of 2- hour glucose of the oral glucose tolerance test, fasting glucose and HbA1c with WMH volume. 
IRRs are from zero- inflated negative binomial regression models
2- hour glucose (n=354) Fasting glucose (n=388) HbA1c (n=388)
IRR (95% CI) P value IRR (95% CI) P value IRR (95% CI) P value
WMH volume A 1.01 (1.01 to 1.02) <0.001 1.00 (0.99 to 1.01) 0.710 2.01 (1.37 to 2.93) <0.001
B 1.01 (1.00 to 1.01) <0.001 1.00 (1.00 to 1.01) 0.455 1.38 (1.05 to 1.81) 0.021
C 1.01 (1.00 to 1.01) <0.001 1.00 (1.00 to 1.01) 0.389 1.23 (1 to 1.51) 0.050
IRRs are from zero- inflated negative binomial regression models.
A, unadjusted; B, adjusted for age and gender; C, adjusted for age, gender, hypertension, low- density lipoprotein cholesterrol, Body Mass 
Index, smoking, and alcohol consumption; HbA1c, glycated hemoglobin; IRR, incidence rate ratio; WMH, white matter hyperintensity.
Figure 3 Visualization of predicted WMH volume (y- axis) according to 2- hour glucose (A, x- axis), fasting glucose (B, x- axis) 
and HbA1c (C, x- axis). Dashed line: unadjusted linear prediction. Solid line: prediction adjusted for age, gender, hypertension, 



















are: first published as 10.1136/bm




7BMJ Open Diab Res Care 2021;9:e002050. doi:10.1136/bmjdrc-2020-002050
Cardiovascular and metabolic risk
might indicate that IGT, defined by OGTT, and IFG, 
defined by fasting glucose levels, have different effects 
on the development of WMHs, especially since IGT and 
IFG have a heterogeneous pathogenesis representing 
different entities in impaired glucose regulation and do 
not necessarily include the same group of participants.31 32 
IGT is related to insulin resistance, whereas IFG is asso-
ciated with impaired insulin secretion.32 Consequently, 
IGT and IFG may induce partially distinct pathological 
mechanisms with differential impact on the develop-
ment of WMHs. Since pre- diabetes comprises both IGT 
and IFG, conflicting results of studies evaluating the 
association between pre- diabetes and WMHs could be 
partially caused by a different distribution of IGT and 
IFG in the underlying study samples of participants with 
pre- diabetes.
The stronger association of 2- hour glucose levels 
than fasting glucose levels or HbA1c with WMH burden 
might be partially explained by the known adverse 
cardiovascular effects of high glucose level variance and 
amplitude. It was demonstrated that glucose variability 
in OGTT was associated with greater arterial stiffness 
and maladaptive arterial remodeling independent of 
HbA1c.33 Glucose variability in continuous glucose moni-
toring showed an HbA1c independent association with 
diabetic retinopathy.34 These findings could indicate that 
glucose dynamics not detected by HbA1c may contribute 
to cardiovascular complications, potentially causing 
increased WMH burden.35 However, further studies are 
needed to assess the independent impact of glucose vari-
ability in OGTT on WMH volume.
We found no significant association between WMH 
burden and fasting plasma glucose across groups. In 
participants with established type 2 diabetes, however, a 
significant association between fasting glucose levels and 
WMHs has been reported previously.36 37 In a population- 
based cohort- study oversampled with type 2 diabetes, 
fasting glucose levels were significantly associated with 
WMH volume.24 In pre- diabetes however, results are 
more ambiguous: a recent cohort study of participants 
with high–normal fasting glucose levels or impaired 
mean fasting glucose levels (ie, pre- diabetes) found no 
significant difference in WMH volume between the two 
groups—at least when including subjects over 40 years 
in the model. When the analysis was restricted to partic-
ipants aged 40 years and younger, the effect of mean 
fasting glucose levels on WMH volume was significant.38
In our study, we found a significant association of HbA1c 
with WMH volume, which was attenuated after adjust-
ment for age, gender and cardiovascular risk factors, 
depending on the underlying study sample. This result 
is in keeping with the current literature: several studies 
have reported that elevated levels of HbA1c are associated 
with high WMH burden.23 39–41 Schneider et al showed in 
a large- scale study that severe diabetes defined by high 
HbA1c and long disease duration but not pre- diabetes 
or less- severe diabetes defined by elevated HbA1c were 
associated with an increased burden of WMHs.23 Tamura 
et al found no association of HbA1c and WMH volume in 
elderly patients with diabetes.35
The results of this study need to be interpreted in light 
of its limitations. Compared with previously published 
studies on WMH volume in pre- diabetes and diabetes,23 24 
our sample size of 388 participants was rather small. Our 
results are not applicable to persons with overt cardio-
vascular disease, as participants with overt cardiovas-
cular disease were excluded by study design, which was 
focused on MRI- based analysis of subclinical disease 
burden. Although traditional cardiovascular risk factors 
such as hypertension, obesity, dyslipidaemia, smoking 
and alcohol consumption were included in the analysis 
model, the existence of unmeasured confounding vari-
ables cannot be fully ruled out. Our results, however, 
indicate that high 2- hour serum glucose concentration in 
OGTT may be an independent risk factor for the devel-
opment of WMHs, especially in pre- diabetes.
In conclusion, in this population without prior cardio-
vascular disease, our results suggest that the effect of 
diabetes and particularly pre- diabetes on WMH volume 
may be driven by 2- hour serum glucose concentration 
determined by OGTT but not by fasting glucose levels. 
Conflicting results of studies evaluating the association 
between WMHs and pre- diabetes could be partially 
caused by the determination of diabetes status by 2- hour 
glucose and fasting glucose levels plus different distri-
bution patterns of IGT and IFG in the underlying study 
samples. Considering the stable association of 2- hour 
glucose with WMH volume, this marker could serve as a 
readily available parameter to inform intensified preven-
tion strategies and to monitor early treatment strate-
gies in individuals at risk of WMH- associated morbidity 
such as stroke, cognitive decline and increased risk of 
depression.
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